Drugs / DST-0509
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03637556 | Aug 2019 → Jun 2021 | beta-thalassemia major | DisperSol Technologies, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DST-0509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03637556 ↗ |
| Known as | deferasirox | “DST-0509 (deferasirox) will be supplied in 360 mg, 180 mg and 90 mg tablets.” NCT03637556 ↗ |